Cape Verde vs Myanmar: Average cost of multi drug-resistant tuberculosis treatment
Cape Verde
500 constant 2022 US$
in 2024
Myanmar
468 constant 2022 US$
in 2024
Cape Verde rank
78th
Myanmar rank
80th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cape Verde
- Myanmar
How they compare
Cape Verde currently reports 500 constant 2022 US$ against 468 constant 2022 US$ in Myanmar, a difference of 32 constant 2022 US$.
That makes Cape Verde's figure about 1.1 times Myanmar's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Cape Verde ahead.
Cape Verde ranks 78th and Myanmar ranks 80th of 92 countries.
Cape Verde has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cape Verde | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,500 constant 2022 US$ | 1,184 constant 2022 US$ | 316 constant 2022 US$ | Cape Verde |
| 2020s | 1,100 constant 2022 US$ | 944 constant 2022 US$ | 156 constant 2022 US$ | Cape Verde |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cape Verde or Myanmar?
- Cape Verde, at 500 constant 2022 US$ against 468 constant 2022 US$ in Myanmar as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cape Verde and Myanmar?
- 32 constant 2022 US$, with Cape Verde ahead.
- How many years of comparable data are there for Cape Verde and Myanmar?
- 8 years are reported by both, from 2017 to 2024.
- How do Cape Verde and Myanmar rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cape Verde ranks 78th and Myanmar ranks 80th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.